Update regarding the phase 2a trials:
"Evaluation of efficacy by measurement of non-vellus Target Area Hair Count (TAHC) showed mean changes from baseline of 24.3 hairs with the high label strength (0.02%) and 20.3 hairs with the low label strength (0.0025%) topical solution, compared to 14.0 hairs with placebo in 1 cm2 test areas; randomization was 1:1:1 with 71 patients enrolled. Both label strengths of TDM-105795 were well tolerated with no material safety issues identified. Bioanalytical results show that once daily application of TDM-105795 topical solution at either dose produced extremely low to no systemic exposure."
Overall:
0.02% once daily - 24.3 TAHC (per cm2)
0.0025% once daily - 20.3 TAHC (per cm2)
Placebo - 14.0 TAHC (per cm2)
Both 0.02% and 0.002% once daily was well tolerated with no material safety issues and extremely low to no systemic exposure.
Source: https://www.prnewswire.com/news-rel...rowth-in-androgenetic-alopecia-302052631.html
"Evaluation of efficacy by measurement of non-vellus Target Area Hair Count (TAHC) showed mean changes from baseline of 24.3 hairs with the high label strength (0.02%) and 20.3 hairs with the low label strength (0.0025%) topical solution, compared to 14.0 hairs with placebo in 1 cm2 test areas; randomization was 1:1:1 with 71 patients enrolled. Both label strengths of TDM-105795 were well tolerated with no material safety issues identified. Bioanalytical results show that once daily application of TDM-105795 topical solution at either dose produced extremely low to no systemic exposure."
Overall:
0.02% once daily - 24.3 TAHC (per cm2)
0.0025% once daily - 20.3 TAHC (per cm2)
Placebo - 14.0 TAHC (per cm2)
Both 0.02% and 0.002% once daily was well tolerated with no material safety issues and extremely low to no systemic exposure.
Source: https://www.prnewswire.com/news-rel...rowth-in-androgenetic-alopecia-302052631.html